These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29934137)

  • 1. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
    Zhang I; Gilbo P; Kohn N; Cox B
    Pract Radiat Oncol; 2018; 8(6):452-457. PubMed ID: 29934137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
    Jadvar H; Challa S; Quinn DI; Conti PS
    Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
    Küronya Z; Sinkovics I; Ágoston P; Bíró K; Bodrogi I; Böde I; Dank M; Gyergyay F; Vajdics T; Kolonics Z; Nagyiványi K; Rúzsa Á; Géczi L
    Pathol Oncol Res; 2017 Oct; 23(4):777-783. PubMed ID: 28074331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
    Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
    Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
    Winter BM; von Rundstedt FC; Grimm MO
    Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
    Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
    Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial Discrepancies in Overall Survival among Men Treated with
    Zhao H; Howard LE; De Hoedt A; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
    J Urol; 2020 Feb; 203(2):331-337. PubMed ID: 31479407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
    Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
    Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience.
    Gazzilli M; Durmo R; Cossalter E; Cerudelli E; Panarotto MB; Albano D; Bertagna F; Giubbini R
    Nucl Med Commun; 2020 Apr; 41(4):300-307. PubMed ID: 32049940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
    BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.